Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open Label Extension Study of Pegunigalsidase Alfa in Fabry Disease
NCT03614234Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2018
- Primary completion
- Apr 2026
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of pegunigalsidase alfa in Fabry disease (FD), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Evaluation of treatment-related adverse events at 364 weeks. Started Nov 2018; status: completed.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT03614234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614234.